Norinchukin Bank The grew its holdings in Zoetis Inc (NYSE:ZTS) by 35.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 91,061 shares of the company’s stock after acquiring an additional 24,031 shares during the period. Norinchukin Bank The’s holdings in Zoetis were worth $6,560,000 as of its most recent SEC filing.
Several other hedge funds have also modified their holdings of the company. FDx Advisors Inc. raised its stake in shares of Zoetis by 23.9% in the 4th quarter. FDx Advisors Inc. now owns 67,741 shares of the company’s stock valued at $4,880,000 after acquiring an additional 13,053 shares during the period. Synovus Financial Corp raised its stake in shares of Zoetis by 7.1% in the 4th quarter. Synovus Financial Corp now owns 44,645 shares of the company’s stock valued at $3,216,000 after acquiring an additional 2,972 shares during the period. American International Group Inc. raised its stake in shares of Zoetis by 5.5% in the 4th quarter. American International Group Inc. now owns 226,915 shares of the company’s stock valued at $16,347,000 after acquiring an additional 11,917 shares during the period. Arrowstreet Capital Limited Partnership raised its stake in shares of Zoetis by 227.9% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 540,047 shares of the company’s stock valued at $38,905,000 after acquiring an additional 375,347 shares during the period. Finally, TCW Group Inc. raised its stake in shares of Zoetis by 12.8% in the 4th quarter. TCW Group Inc. now owns 1,112,368 shares of the company’s stock valued at $80,136,000 after acquiring an additional 126,439 shares during the period. 92.45% of the stock is currently owned by institutional investors and hedge funds.
In other news, EVP Roxanne Lagano sold 35,663 shares of Zoetis stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $81.02, for a total value of $2,889,416.26. Following the completion of the transaction, the executive vice president now directly owns 49,919 shares of the company’s stock, valued at approximately $4,044,437.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Roman Trawicki sold 23,885 shares of Zoetis stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $82.00, for a total transaction of $1,958,570.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 105,569 shares of company stock valued at $8,594,429. 0.31% of the stock is owned by company insiders.
Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 15th. The company reported $0.69 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.66 by $0.03. The company had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.40 billion. Zoetis had a net margin of 16.28% and a return on equity of 65.96%. The firm’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same period last year, the business earned $0.47 EPS. sell-side analysts predict that Zoetis Inc will post 3.04 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 1st. Shareholders of record on Friday, April 20th will be issued a dividend of $0.126 per share. This represents a $0.50 annualized dividend and a yield of 0.60%. The ex-dividend date of this dividend is Thursday, April 19th. Zoetis’s dividend payout ratio is currently 22.94%.
A number of equities analysts have recently commented on ZTS shares. Cowen set a $80.00 target price on shares of Zoetis and gave the company a “buy” rating in a research note on Friday, November 17th. UBS Group reissued a “neutral” rating on shares of Zoetis in a research note on Friday, November 24th. Morgan Stanley raised shares of Zoetis from an “equal weight” rating to an “overweight” rating and set a $80.00 target price on the stock in a research note on Wednesday, November 29th. Cantor Fitzgerald set a $80.00 price target on shares of Zoetis and gave the company a “buy” rating in a report on Tuesday, December 12th. Finally, Craig Hallum reaffirmed a “buy” rating and set a $85.00 price target (up from $77.00) on shares of Zoetis in a report on Tuesday, January 2nd. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. Zoetis has an average rating of “Buy” and a consensus price target of $80.28.
TRADEMARK VIOLATION NOTICE: This report was originally reported by Week Herald and is owned by of Week Herald. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://weekherald.com/2018/03/14/zoetis-inc-zts-shares-bought-by-norinchukin-bank-the-2.html.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.